Doxorubicin-docetaxel sequential schedule: Results of front-line treatment in advanced breast cancer

S. Palmeri, V. Leonardi, M. Tamburo De Bella, A. Morabito, M. Vaglica, V. Accurso, F. Ferraù, G. Failla, B. Agostara, B. Massidda, R. Valenza, M. Fanelli, Giampietro Gasparini

Research output: Contribution to journalArticlepeer-review


Objective: We conducted a multi-institutional phase II study to evaluate the tolerability and activity of a sequential schedule of treatment with doxorubicin and docetaxel in chemotherapy-naive women with advanced breast cancer. Methods: A total of 73 patients with PS (ECOG) 0-2, aged 2 by intravenous (i.v.) 30 min injection on day 1 followed the day after by docetaxel 75 mg/m2, by i.v. 60 min infusion. Cycles were repeated every 28 days. Results: Overall, the median number of administered cycles was 6 (range 1-14). The most common toxicity was hematological, with 56.2% of the patients who experienced grade 3-4 neutropenia. However, febrile neutropenia occurred only in 2.8% of the cases. The median cumulative dose of doxorubicin was 350 mg/m2 (range 50-700 mg/m2). Eleven patients (15.4%) were documented to have >10% but

Original languageEnglish
Pages (from-to)205-212
Number of pages8
Issue number3
Publication statusPublished - 2002


  • Advanced breast cancer
  • Docetaxel
  • Doxorubicin
  • Phase II trial

ASJC Scopus subject areas

  • Cancer Research
  • Oncology


Dive into the research topics of 'Doxorubicin-docetaxel sequential schedule: Results of front-line treatment in advanced breast cancer'. Together they form a unique fingerprint.

Cite this